- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03914417
Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
December 30, 2020 updated by: Sharon Rose, Icahn School of Medicine at Mount Sinai
An Investigator-initiated Study to Evaluate Genomic Markers of Immune Infiltration Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream
The study team had plans to treat approximately 30 subjects.
Each subject that had qualified had at least 4-8 visible AKs on the face and/or scalp.
At Day 0, one Actinic Keratosis (AK) in the treatment area had been biopsied via a 3 mm punch.
The tissue collected was sent to pathology for confirmatory diagnosis as well as genomic analysis.
The remaining AKs had been identified, photographed, and documented on a transparency.
One of the remaining AKs was designated as the target lesion.
The patient returned to the clinic in 7 days (+/- 3) for suture removal.
Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream.
Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen.
Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
At week 14, a biopsy via a 3 mm punch was done of the target lesion.
Yet, if the target lesion was no longer present, a biopsy was done at the site where the lesion was previously located.
Study Overview
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults at least 18 years old.
- Subjects must be in good general health as confirmed by the medical history.
- Subjects must be able to read, sign, and understand the informed consent.
- Prior to imiquimod therapy, subjects must have at least 4-8 actinic keratoses on the face and/or scalp.
- Subject must be willing to forego any other treatments on the face and/or scalp, including tanning bed use and excessive sun exposure while in the study.
- Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions.
- If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study.
Exclusion Criteria:
- Subjects with a history of melanoma anywhere on the body.
- Subjects with an unstable medical condition as deemed by the clinical investigator.
- Subjects with non-melanoma skin cancer on the face and/or or scalp.
- Subjects with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of AKs.
- Subjects who have previously been treated with imiquimod: on the face or scalp in the past 6 months; or outside of the study area within the past 30 days.
- Women who are pregnant, lactating, or planning to become pregnant during the study period.
- Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc).
- Subjects who have active chemical dependency or alcoholism as assessed by the investigator.
- Subjects who have known allergies to any excipient in the study cream.
- Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device on the study area within 30 days prior to study treatment initiation.
Subjects who have received any of the following within 90 days prior to study treatment initiation:
- interferon or interferon inducers
- cytotoxic drugs
- immunomodulators or immunosuppressive therapies (inhaled/ intranasal steroids are permitted)
- oral or parenteral corticosteroids
- topical corticosteroids if greater than 2 mg/day
- any dermatologic procedures or surgeries on the study area (including any AK treatments)
- Subjects who have used any topical prescription medications on the study area within 30 days prior to study treatment initiation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imiquimod 3.75% cream
applied topically
|
Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream.
Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen.
Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Responders
Time Frame: Day 70
|
The number of participants with reduction in number of AKs on the face and/or scalp after application of imiquimod 3.75%.
|
Day 70
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Treatment Related Adverse Events
Time Frame: Day 70
|
The safety of imiquimod 3.75% on the face and/or scalp was determined by the number of treatment related adverse events that occur during the study.
|
Day 70
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sharon Rose, MD, Icahn School of Medicine at Mount Sinai
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
April 30, 2015
Study Completion (Actual)
April 30, 2015
Study Registration Dates
First Submitted
May 3, 2017
First Submitted That Met QC Criteria
April 11, 2019
First Posted (Actual)
April 16, 2019
Study Record Updates
Last Update Posted (Actual)
January 20, 2021
Last Update Submitted That Met QC Criteria
December 30, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 13-1215
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Imiquimod 3.75% Cream
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Graceway Pharmaceuticals, LLCCompletedGenital WartsUnited States
-
Taro Pharmaceuticals USACompleted
-
Medicis Global Service CorporationUnknownActinic KeratosisUnited States
-
Actavis Mid-Atlantic LLCCompleted
-
Teva Pharmaceuticals USACompletedActinic KeratosisUnited States
-
Medical University of GrazCompleted
-
Rochester General HospitalBausch Health Americas, Inc.; Rochester Skin Lymphoma Medical Group, PLLCWithdrawn
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States
-
Graceway Pharmaceuticals, LLCCompletedKeratosisUnited States